Long Ideas - Sucampo Pharmaceuticals (NASDAQ:SCMP) reported 2Q 2012 revenues of $16.7 million, up 19.2% year over year. Evidence that the company’s treatment for irritable bowel syndrome (IBS), … Continue Reading
Read NowLong Ideas - The recent sharp decline in Halozyme Therapeutics (NASDAQ:HALO) last week in fact presented a major buying opportunity for investors, with the shares up roughly 57% … Continue Reading
Read NowLong Ideas - Amarin’s (NASDAQ:AMRN) sell-off following the largely anticipated FDA approval of Vascepa has given investors a chance to buy the stock at an attractive valuation. However, … Continue Reading
Read NowLong Ideas - Coronado Biosciences (NASDAQ:CNDO) announced that an investigator-sponsored Phase II clinical trial has begun evaluating the company’s novel immunotherapy in patients with ulcerative colitis (UC). CNDO-201, … Continue Reading
Read NowLong Ideas - The Celsion Corporation (NASDAQ:CLSN) in collaboration with Royal Phillips Electronics (NYSE:PHG) announced this morning that the FDA has approved a Phase II clinical trial of … Continue Reading
Read NowLong Ideas - After its Q2 earnings report was released last night, Obagi Medical Products (NASDAQ:OMPI) took a dive this morning, down 22.5% just after the bell. The … Continue Reading
Read NowLong Ideas - The FDA has two new drugs in its queue this morning after GlaxoSmithKline (NYSE:GSK) submitted two new melanoma treatments, dabrafenib and trametinib, to the U.S. … Continue Reading
Read Now